Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrekibart Alone or With Mirikizumab in Ulcerative Colitis
NCT06598943Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2024
- Primary completion
- Aug 2026
- Modality
- IgG Antibodies, PD-1/PD-L1 Inhibitors, Anti-inflammatory mAbs
- Countries
- 21
01
Overview
A Phase 2 trial of eltrekibart in ulcerative colitis (UC), sponsored by Eli Lilly and Company. Started Oct 2024; status: active, not recruiting.
02
Drugs
eltrekibart
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06598943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06598943.